Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Povorcitinib (JAK1) in Prurigo nodularis. The expected timing is based on the latest available company guidance and may change.
STOP-PN1, STOP-PN2 Ph3 trials. Phase 2 study completed enrollment, 10/31/23 Positive Ph2 data. 7/29/25- Two Ph3 trials ongoing with data in 2026. 03/28/26:- Topline Phase 3 prurigo nodularis data anticipated in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.